WashU Medicine researcher Kanta Horie, PhD, places a sample in a mass spectrometer that measures protein levels in blood plasma and other fluids. Horie co-led the development of a blood test for Alzheimer’s disease that diagnoses and stages the disease by using mass spectrometry to measure the level of a protein called MTBR-tau243.
BYLINE: Tamara Schneider
Newswise — A newly developed blood test for Alzheimer’s disease not only aids in the diagnosis of the neurodegenerative condition but also indicates how far it has progressed, according to a study by researchers at Washington University School of Medicine in St. Louis and Lund University in Sweden.
Several blood tests for Alzheimer’s disease are already clinically available, including two based on technology licensed from WashU. Such tests help doctors diagnose the disease in people with cognitive symptoms, but do not indicate the clinical stage of the disease symptoms – that is, the degree of impairment in thinking or memory due to Alzheimer’s dementia. Current Alzheimer’s therapies are most effective in early stages of the disease, so having a relatively easy and reliable way to gauge how far the disease has progressed could help doctors determine which patients are likely to benefit from drug treatment and to what extent. The new test can also provide insight on whether a person’s symptoms are likely due to Alzheimer’s versus some other cause.
The study is published March 31 in Nature Medicine.
In the study, the researchers found that levels of a protein called MTBR-tau243 in the blood accurately reflect the amount of toxic accumulation of tau aggregates in the brain and correlate with the severity of Alzheimer’s disease. Analyzing blood levels of MTBR-tau243 from a group of people with cognitive decline, the researchers were able to distinguish between people with early- or later-stage Alzheimer’s disease and separate both groups of Alzheimer’s patients from people whose symptoms were caused by something other than Alzheimer’s disease.
“This blood test clearly identifies Alzheimer’s tau tangles, which is our best biomarker measure of Alzheimer’s symptoms and dementia,” said co-senior author Randall J. Bateman, MD, the Charles F. and Joanne Knight Distinguished Professor of Neurology at WashU Medicine. “In clinical practice right now, we don’t have easy or accessible measures of Alzheimer’s tangles and dementia, and so a tangle blood test like this can provide a much better indication if the symptoms are due to Alzheimer’s and may also help doctors decide which treatments are best for their patients.”
Tracking Alzheimer’s disease progression from blood
Alzheimer’s disease involves a build-up of a protein, called amyloid, into plaques in the brain, followed by the development of tangles of tau protein years later. Cognitive symptoms emerge around the time tau tangles become detectable, and symptoms worsen as the tangles spread. The gold standard for staging Alzheimer’s disease is positron emission tomography (PET) brain scans for amyloid plaques and tau tangles. Amyloid scans yield information about the presymptomatic and early symptomatic stages, while tau scans are useful for tracking later stages of the disease. PET brain scans are highly accurate but expensive, time-consuming and frequently unavailable outside of major research centers, so they are not widely used.
Bateman leads a team that is developing blood tests for Alzheimer’s disease as a more accessible alternative to brain scans. They have developed two blood tests that correlate closely with the amount of amyloid plaques in the brain. Both are now used by doctors to aid diagnosis. But until now, there has been no blood test that reports on tau levels in the brain.
In a previous study, Bateman and colleagues — including co-first authors Kanta Horie, PhD, a research associate professor of neurology at WashU Medicine, and Gemma Salvadó, PhD, then a postdoctoral researcher at Lund University, and co-senior author Oskar Hansson, MD, PhD, a professor of neurology at Lund University — showed that cerebrospinal fluid levels of MTBR-tau243 correlate closely with tau tangles in the brain. In the current study, the team extended the analysis to blood. A blood sample is easier to collect than cerebrospinal fluid, which is obtained via spinal tap.
The researchers developed a technique to measure MTBR-tau243 levels in people’s blood and compared it to the amount of tau tangles in their brains as measured by brain scans. They piloted the approach on data from two cohorts: volunteers at WashU Medicine’s Charles F. and Joanne Knight Alzheimer Disease Research Center, which included 108 people, and a subset of 55 people from the Swedish BioFINDER-2 cohort. To assess whether the approach was generalizable, they validated it in an independent dataset consisting of the remaining 739 people in the BioFINDER-2 cohort.
The people in the two cohorts represented all but the most severe end of the spectrum of Alzheimer’s disease, from the presymptomatic stage when brain amyloid levels are elevated but people remain cognitively healthy, through early-stage disease with mild cognitive impairments, to late symptomatic disease when patients exhibit full-blown dementia. For comparison, cognitively healthy people with normal amyloid levels, and people with cognitive symptoms due to conditions other than Alzheimer’s disease, were included.
The researchers’ analysis showed that blood MTBR-tau243 levels reflected the amount of tau tangles in the brain with 92% accuracy. MTBR-tau243 levels in the blood were normal in asymptomatic people regardless of amyloid status, meaning that blood MTBR-tau243 levels do not change between healthy people and people in the presymptomatic stage of Alzheimer’s disease with amyloid plaques.
Among people with cognitive symptoms due to Alzheimer’s disease, MTBR-tau243 levels were significantly elevated for people in the mild cognitive impairment phase of Alzheimer’s disease and much higher — up to 200 times — for those in the dementia phase. Those differences translated into clear separation of people in early- and late-stage Alzheimer’s disease. At the same time, MTBR-tau243 levels were normal in people with cognitive symptoms due to diseases other than Alzheimer’s, meaning that the test effectively distinguished Alzheimer’s dementia from other kinds of dementia.
The technology underlying the blood test for tau aggregates has been licensed by WashU to C2N Diagnostics, a WashU startup that developed the blood tests for amyloid. These amyloid tests incorporate measures of another form of tau called p-tau217.
“I believe we will use blood-based p-tau217 to determine whether an individual has Alzheimer’s disease, but MTBR-tau243 will be a highly valuable complement in both clinical settings and research trials,” said Hansson. “When both of these biomarkers are positive, the likelihood that Alzheimer’s is the underlying cause of a person’s cognitive symptoms increases significantly, compared to when only p-tau217 is abnormal. This distinction is crucial for selecting the most appropriate treatment for each patient.”
Blood tests could inform personalized Alzheimer’s treatment
Two Alzheimer’s therapies have been approved by the Food and Drug Administration (FDA) to slow progression of the disease, and both work by lowering amyloid levels in the brain. Horie said the number and variety of available Alzheimer’s medications may soon be expanding, as several experimental drugs that target tau or other aspects of Alzheimer’s disease are in the pipeline. With blood tests to diagnose and stage the disease, doctors would be able to tailor treatments to the patient’s particular disease state.
“We’re about to enter the era of personalized medicine for Alzheimer’s disease,” Horie said. “For early stages with low tau tangles, anti-amyloid therapies could be more efficacious than in late stages. But after the onset of dementia with high tau tangles, anti-tau therapy or one of the many other experimental approaches may be more effective. Once we have a clinically available blood test for staging, plus treatments that work at different stages of the disease, doctors will be able to optimize their treatment plans for the specific needs of each patient.”
Horie K, Salvadó G, Koppisetti RK, Janelidze S, Barthélemy NR, He Y, Sato C, Gordon BA, Jiang H, Benzinger TLS, Erik Stomrud E, Holtzman DM, Mattsson-Carlgren N, Morris JC, Palmqvist S, Ossenkoppele R, Schindler SE, Hansson O, Bateman RJ. Plasma MTBR-tau243 identifies tau tangle pathology in Alzheimer’s disease. Nature Medicine. March 31, 2025. DOI: 10.1038/s41591-025-03617-7.
This work was supported by the Charles F. and Joanne Knight Alzheimer Disease Research Center; the Tracy Family SILQ Center; the National Institutes of Health (NIH), grant number R01AG070941; the Alzheimer’s Association’s Zenith Award; the Hope Center for Neurological Disorders; and the Department of Neurology at WashU Medicine. The Swedish BioFINDER-2 study was supported by the U.S. National Institute on Aging, grant number R01AG083740, the European Research Council, grant number ADG-101096455; the Alzheimer’s Association, grant numbers ZEN24-1069572 and SG-23-1061717; the GHR Foundation; the Swedish Research Council, grant numbers 2022-00775, 2021-02219, and 2018-02052; ERA PerMed, grant number ERAPERMED2021-184; the Knut and Alice Wallenberg foundation, grant number 2022-0231; the Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson’s disease) at Lund University; the Swedish Alzheimer Foundation, grant numbers AF-980907, AF-994229, and AF-994075; the Swedish Brain Foundation, grant numbers FO2021-0293, FO2023-0163 and FO2022-0204; the Wallenberg AI, Autonomous Systems and Software Program (WASP) and the SciLifeLab and Wallenberg National Program for Data-Driven Life Science (DDLS) joint call for research projects, grant number WASP/DDLS22-066; the Parkinson foundation of Sweden, grant number 1412/22; the Cure Alzheimer’s fund; the Rönström Family Foundation; the Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse; the Skåne University Hospital Foundation, grant number 2020-O000028; the Regionalt Forskningsstöd, grant number 2022-1259; and the Swedish federal government under the ALF agreement, grant numbers 2022-Projekt0080 and 2022-Projekt0107. Gemma Salvadó received funding from the European Union’s Horizon 2020 Research and Innovation Program under Marie Sklodowska-Curie action grant agreement number 101061836; the Alzheimer’s Association, fellowship number AARF-22-972612; the Alzheimerfonden, grant number AF-980942; BrightFocus Foundation, fellowship number A2024007F; Greta och Johan Kocks; and the Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson’s Disease) at Lund University.
The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
About Washington University School of Medicine
WashU Medicine is a global leader in academic medicine, including biomedical research, patient care and educational programs with 2,900 faculty. Its National Institutes of Health (NIH) research funding portfolio is the second largest among U.S. medical schools and has grown 56% in the last seven years. Together with institutional investment, WashU Medicine commits well over $1 billion annually to basic and clinical research innovation and training. Its faculty practice is consistently within the top five in the country, with more than 1,900 faculty physicians practicing at 130 locations and who are also the medical staffs of Barnes-Jewish and St. Louis Children’s hospitals of BJC HealthCare. WashU Medicine has a storied history in MD/PhD training, recently dedicated $100 million to scholarships and curriculum renewal for its medical students, and is home to top-notch training programs in every medical subspecialty as well as physical therapy, occupational therapy, and audiology and communications sciences.
